ARL6IP5 and gastric carcinoma: Notably, they discovered that ARL6IP5 had contrasting effects on XRCC1 in gastric carcinoma cells compared to their normal counterparts; on gastric carcinoma cells ARL6IP5-OE decreased XRCC1 levels, while in their normal counterparts ARL6IP5-OE increased XRCC1 levels.